<!DOCTYPE html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        
        
        
        <link rel="shortcut icon" href="../../img/favicon.ico">
        <title>Immunotherapies in Haematology - MediWiki</title>
        <link href="../../css/bootstrap.min.css" rel="stylesheet">
        <link href="../../css/font-awesome.min.css" rel="stylesheet">
        <link href="../../css/base.css" rel="stylesheet">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/styles/color-brewer.min.css">
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/11.8.0/highlight.min.js"></script>
        <script>hljs.highlightAll();</script> 
    </head>

    <body>
        <div class="navbar fixed-top navbar-expand-lg navbar-dark bg-primary">
            <div class="container">
                <a class="navbar-brand" href="../..">MediWiki</a>
                <!-- Expander button -->
                <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#navbar-collapse">
                    <span class="navbar-toggler-icon"></span>
                </button>

                <!-- Expanded navigation -->
                <div id="navbar-collapse" class="navbar-collapse collapse">
                        <!-- Main navigation -->
                        <ul class="nav navbar-nav">
                            <li class="navitem">
                                <a href="../../Basic%20Clinical%20Sciences.html" class="nav-link">Basic Clinical Sciences</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Internal%20Medicine.html" class="nav-link">Internal Medicine</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Surgery.html" class="nav-link">Surgery</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Psychiatry.html" class="nav-link">Psychiatry</a>
                            </li>
                            <li class="navitem">
                                <a href="../../Critical%20Care.html" class="nav-link">Critical Care</a>
                            </li>
                        </ul>

                    <ul class="nav navbar-nav ml-auto">
                        <li class="nav-item">
                            <a href="#" class="nav-link" data-toggle="modal" data-target="#mkdocs_search_modal">
                                <i class="fa fa-search"></i> Search
                            </a>
                        </li>
                            <li class="nav-item">
                                <a rel="prev" href="../Haematology/Urothelial%20cancer.html" class="nav-link">
                                    <i class="fa fa-arrow-left"></i> Previous
                                </a>
                            </li>
                            <li class="nav-item">
                                <a rel="next" href="../Infectious%20Diseases/Antifungal%20agents.html" class="nav-link">
                                    Next <i class="fa fa-arrow-right"></i>
                                </a>
                            </li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="container">
            <div class="row">
                    <div class="col-md-3"><div class="navbar-light navbar-expand-md bs-sidebar hidden-print affix" role="complementary">
    <div class="navbar-header">
        <button type="button" class="navbar-toggler collapsed" data-toggle="collapse" data-target="#toc-collapse" title="Table of Contents">
            <span class="fa fa-angle-down"></span>
        </button>
    </div>

    
    <div id="toc-collapse" class="navbar-collapse collapse card bg-secondary">
        <ul class="nav flex-column">
            
            <li class="nav-item" data-level="1"><a href="#immunotherapies-in-haematology" class="nav-link">Immunotherapies in Haematology</a>
              <ul class="nav flex-column">
            <li class="nav-item" data-level="2"><a href="#immunotherapies-in-haematological-cancers" class="nav-link">Immunotherapies in haematological cancers</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#classes-of-anti-tumour-immunotherapy" class="nav-link">Classes of anti-tumour immunotherapy</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#t-cell-immunotherapy-and-car-t-cells" class="nav-link">T-cell immunotherapy and CAR-T cells</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#natural-killer-cell-immunotherapy" class="nav-link">Natural killer cell immunotherapy</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#moa" class="nav-link">MOA</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#monoclonal-antibodies" class="nav-link">Monoclonal antibodies</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#drug-or-toxin-conjugation" class="nav-link">Drug or toxin conjugation</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#bispecific-t-cell-engagers" class="nav-link">Bispecific T-cell engagers</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#immune-checkpoint-inhibitor" class="nav-link">Immune checkpoint inhibitor</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#normal-t-cell-activation" class="nav-link">Normal T-cell activation</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#immunomodulatory-drugs" class="nav-link">Immunomodulatory drugs</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#examples_4" class="nav-link">Examples</a>
              <ul class="nav flex-column">
              </ul>
            </li>
            <li class="nav-item" data-level="2"><a href="#immunotherapeutic-vaccines" class="nav-link">Immunotherapeutic vaccines</a>
              <ul class="nav flex-column">
              </ul>
            </li>
              </ul>
            </li>
        </ul>
    </div>
</div></div>
                    <div class="col-md-9" role="main">

<h1 id="immunotherapies-in-haematology">Immunotherapies in Haematology</h1>
<p>BPT learning points
- Broad pharmacological principles and complications of immunotherapy and molecularly targeted therapy</p>
<h2 id="immunotherapies-in-haematological-cancers">Immunotherapies in haematological cancers</h2>
<ul>
<li>Advantages and use cases<ul>
<li>immune responsiveness - allogeneic stem cell transplant and donor lymphocyte infusion<ul>
<li>immune cells from donor can set up immune response</li>
<li>collecting donor lymphcytes and infusing in recipient can ramp up immune response and mop up outstanding malignant cells</li>
</ul>
</li>
<li>malignancies are located close to sites of immune monitoring - e.g. lymph nodes, bone marrow, blood<ul>
<li>immune cells are prone to attack and recognition</li>
</ul>
</li>
<li>cellular origins of malignancy are related to immunity - the same as the effector cells which we use<ul>
<li>can develop effector cells which do not allow escape</li>
</ul>
</li>
<li>feasibility of isolating and mainpuating malignant cells<ul>
<li>easy to access biologic material - bone marrow biopsies<ul>
<li>low risk procedures, can provide large amounts of 'material of interest' - can be prformed before OR after immunotherapy</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>Challenges<ul>
<li>malignant cells can be stimulated by the same stimulatory signals as the immune system<ul>
<li>e.g inflammatory cytokines</li>
<li>difficult if effect cell provides cytokines which then stimulates malignant cells to grow<ul>
<li>need to tease out helpful cytokines</li>
</ul>
</li>
</ul>
</li>
<li>ability of malignant cells to suppress and evade the immune system<ul>
<li>monoclonal antibody use - demonstrated malignant cells suppressing and evading immune system</li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="classes-of-anti-tumour-immunotherapy">Classes of anti-tumour immunotherapy</h2>
<ol>
<li>Cancer vaccines<ul>
<li>vaccinating host to tumour associated antigens</li>
<li>T-cell response â†’ recognise and kills cancer cells</li>
<li>to date, this has not lived up to expected goals</li>
</ul>
</li>
<li>Adoptive immunotherapy<ul>
<li>active and increase T-cell numbers</li>
<li>e.g. development of CAR-T cells<ul>
<li>good response in conditions they are used</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Immunomodulation</p>
<ul>
<li>use drugs to<ul>
<li>increase immune stimulation</li>
<li>overcome immune inhibition - e.g. PD-1 inhibitor and CTLA-4 inhibitors<ul>
<li>changed response to previously untreatable cancers (E.g. metastatic melanoma)
<img alt="" src="../../figures/Pasted%20image%2020231106135936.png" /></li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Hematopoietic SCT - first developed in 1950s, allowed bone marrow to repopulate with incoming cells</p>
<ul>
<li>graft vs. leukemic effect</li>
<li>graft vs disease effect - better relapse</li>
</ul>
</li>
<li>Natural killer cells - becoming more topical; effective at killing tumor cells<ul>
<li>advantage over T-cells as they do not set up Graft-vs-Host disease</li>
<li>CAR-NK cell may give rise to off-the-shelf immunotherapy and haem malignancies</li>
</ul>
</li>
<li>monoclonal antibodies - &gt;. 20 years since rituximab against CD20 B-cell malignancies<ul>
<li>monoclonal-toxin drugs developed since</li>
<li>T-cell engagers related</li>
</ul>
</li>
<li>Immunomodulatory drugs - e.g. thalidomide related drugs in haematological drugs (originally developed against multiple myeloma, thought to act on blood vessel growth)</li>
<li>Bi-specific T-cell engagers<ul>
<li>made of synthetic molcules (Fc receptors against a single antigen, typically CD3 on T-cells and Fc receptors against tumour associated antigen, joined by peptides and bring a T-cell close to target cell for destruction)</li>
</ul>
</li>
<li>T-cell immunotherapy - haem malignancy dramatic improvement<ul>
<li>synthetic TCR to bind tumour associated antigens â†’ activate T-cell â†’ target tumour cell</li>
<li>promising therapy for future</li>
</ul>
</li>
<li>Immune checkpoint inhibitors<ul>
<li>used in melanoma and haematological conditions</li>
<li>increase T-cell killing of tumour cells</li>
</ul>
</li>
<li>Immunotherapeutic vaccines<ul>
<li>originally promising in melanoma but has fallen out of favour due to poorer efficacy</li>
</ul>
</li>
</ol>
<hr />
<h2 id="t-cell-immunotherapy-and-car-t-cells">T-cell immunotherapy and CAR-T cells</h2>
<h3 id="chimeric-antigen-receptor-t-cell-car-t-cells">Chimeric antigen receptor T-cell (CAR-T cells)</h3>
<ul>
<li>Synthetic TCR - recognises and eliminates cells expressing tumor associated antigens (TAAs)<ul>
<li>TAAs give specificity for tumours, less off-target effects</li>
</ul>
</li>
<li>initial studies<ul>
<li>directed against CD19 - ALL, CLL, B-cell lymphoma</li>
<li>2010 - regression of advanced follicular lymphoma using anti-CD19 CAR-T</li>
<li>2013 - rapid tumour eradication and achievement of clinical regression in adult patients with refractory B-ALL</li>
<li>2015 - relapsed/refractory CLL - ORR 57%, CR 29%, 4+ year CAR-T cell persistance with no relapse during time</li>
<li>2015 - DLBCL NHL treated with CAR-T cell therapy with 8/15 entering complete remission</li>
</ul>
</li>
<li>Limitations<ul>
<li>Cytokine release syndrome<ul>
<li>Neurotoxicity - Immune Effect Cell-associated neurotoxicity syndrome (ICANS)<ul>
<li>Delirium, seizure, encephalopathy</li>
<li>can lead to long term morbidity/mortality</li>
</ul>
</li>
<li>Management<ul>
<li>IL6 and IL6R antagonists<ul>
<li>Tocilizumab (anti-IL6R)</li>
<li>Siltuximab (anti-IL6)</li>
</ul>
</li>
<li>Corticosteroids if refractory to IL-6 therapies</li>
</ul>
</li>
</ul>
</li>
<li>On-target off-tumor toxicity<ul>
<li>CD19 on both malignant and non-malignant B-cells</li>
<li>B-cell aplasia and hypogammaglobulinaemia</li>
<li>Management<ul>
<li>IVIg replacement</li>
</ul>
</li>
</ul>
</li>
<li>Downregulation of target antigens or tumour antigen heterogeneity<ul>
<li>CD-19 positive B-cell tumours good at downregulating target antigen</li>
<li>Tumour relapse - common in CD19+ B-cell malignancies</li>
<li>Management<ul>
<li>Use more than 1 CAR T-cells that target different antigens</li>
<li>Bispecific CAR-T cells or multiple single target CAR-T cells</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<hr />
<h2 id="natural-killer-cell-immunotherapy">Natural killer cell immunotherapy</h2>
<h2 id="moa">MOA</h2>
<ul>
<li>Attack tumour cells<ul>
<li>Missing self-recognition<ul>
<li>activation normally inhibited by the interaction with MHC-I molecules</li>
<li>many cancer cells downregulate MHC-I to avoid CD8+ T-cells â†’ opens up possibility of NK cell taking up malignant cell</li>
</ul>
</li>
<li>Induced self-recognition - overexpression of ligands for NK activating receptors</li>
</ul>
</li>
<li>CAR NK cells<ul>
<li>potential for off-the-shelf or universal therapeutic cells</li>
<li>no <a href="../Haematology/Graft%20vs%20Host%20Disease%20%28GvHD%29.html">Graft vs Host Disease (GvHD)</a></li>
<li>not yet used in practice</li>
</ul>
</li>
<li>Clinical trials<ul>
<li>CD19, CD22, B-cell maturation antigen (BCMA), CD33, CD7<ul>
<li>BCMA on <a href="../Haematology/Multiple%20Myeloma.html">Multiple Myeloma</a> cells</li>
<li>CD33 on <a href="../Haematology/AML.html">AML</a> cells </li>
<li>CD7 on T-cells</li>
</ul>
</li>
<li>Phase I and II trials<ul>
<li>Anti-CD19 CAR and Relase refractory CD19 cancers</li>
<li>8/11 participants had objective response, 7 achieved complete remission</li>
</ul>
</li>
</ul>
</li>
<li>Limitations<ul>
<li>Loss of target antigens</li>
<li>Tumour heterogeneity - some cells have target antigen, some don't</li>
<li>Suppressive tumour microenvironment - complicates treatment, </li>
</ul>
</li>
</ul>
<hr />
<h2 id="monoclonal-antibodies">Monoclonal antibodies</h2>
<h3 id="moa_1">MOA</h3>
<ul>
<li>Antibody-dependent cellular cytotoxicity (ADCC)<ul>
<li>NK cell mediated</li>
<li>Monoclonal antibodies directed against TAAs </li>
</ul>
</li>
</ul>
<h3 id="examples">Examples</h3>
<ul>
<li>Rituximab - CD20<ul>
<li>B-cell lymphomas, CLL, Mantle cell lymphoma</li>
<li>some autoimmune conditions</li>
</ul>
</li>
<li>Ofatumumab and Obinutuzumab<ul>
<li>humanised monoclonal antibodies - interact with different CD20 epitope</li>
<li>greater ADCC and antitumor effect compared to rituximab</li>
</ul>
</li>
<li>Daratumumab<ul>
<li>mAb against CD38 antigen</li>
<li>used in <a href="../Haematology/Multiple%20Myeloma.html">Multiple Myeloma</a></li>
<li>Single agent - Relapse refractory after &gt;= 3 lines of therapy in MM</li>
<li>In combinations - RR after failure of &gt;=1 therapy and/or ineligible for autograft<ul>
<li>used w/ immunomodulatory and proteasome inhibitor combinations</li>
</ul>
</li>
</ul>
</li>
<li>Elotuzumab<ul>
<li>anti-SLAMF7 or CS1</li>
<li>single agent use showed no objective response and stable disease in 26%</li>
<li>Combined with lenalidomide/dexamethasone showed ORR 79% and median PFS 14.9 months in randomised phase 3 study in heavily pre-treated population</li>
<li>PBS listed</li>
</ul>
</li>
</ul>
<hr />
<h2 id="drug-or-toxin-conjugation">Drug or toxin conjugation</h2>
<h3 id="examples_1">Examples</h3>
<ul>
<li>Moxetumomab pasudotox<ul>
<li>CD22 antigen</li>
<li>Pseudomonas exotoxin A</li>
<li>Not PBS listed</li>
<li>Treatment of hairy cell leukemia in trials</li>
</ul>
</li>
<li>Polatuzumab vedotin<ul>
<li>CD79 antigen</li>
<li>conjugated with Monomethyl Auristatin (MMAE)</li>
<li>used in R/R DLBCL NHL in medically unfit patients - PBS listed</li>
</ul>
</li>
<li>Brentuximab Vedotin<ul>
<li>MMAE against CD30 (HL, Reed-Sternberg cells and some AML cells)</li>
<li>PBS listed for CD30 positive systemic anaplastic large cell and R/R classical HL</li>
</ul>
</li>
</ul>
<hr />
<h2 id="bispecific-t-cell-engagers">Bispecific T-cell engagers</h2>
<ul>
<li>2 single chain bariable fragments bind to two different agents<ul>
<li>just the binding segment between CD3 and TAA (tumor asociated antigen)</li>
</ul>
</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231106142148.png" /></p>
<h3 id="examples_2">Examples</h3>
<ul>
<li>Blinatumomab<ul>
<li>CD3 (T-cell) to CD19 (B-cell)</li>
<li>investigated for other B-cell malignancies</li>
</ul>
</li>
<li>BiTE (BI 835909)<ul>
<li>BCMA on <a href="../Haematology/Multiple%20Myeloma.html">Multiple Myeloma</a></li>
<li>Fc fragments with BCMA specific fragments</li>
</ul>
</li>
<li>In development<ul>
<li>CD3-CD33 BiTEs for AML</li>
<li>Bispecific NK cell engagers (BiKE)</li>
</ul>
</li>
</ul>
<hr />
<h2 id="immune-checkpoint-inhibitor">Immune checkpoint inhibitor</h2>
<h3 id="moa_2">MOA</h3>
<ul>
<li>Activation of effective T-cells<ul>
<li>needs two-level activation or inhibition</li>
<li>ensures proper effector T-cell functioning - immune checkpoints</li>
</ul>
</li>
<li>Activation phase<ol>
<li>Binding to peptide antigen</li>
<li>Binding B7-1 family ligand</li>
</ol>
</li>
<li>Inhibition<ul>
<li>Different hematopoitic meliangicies upregulating expression of PD-1 and CTLA4</li>
<li>Targeting immune checkpoint inhibitors has revolutionised cancer treatment - initially melanoma, but now for a large variety</li>
</ul>
</li>
</ul>
<h2 id="normal-t-cell-activation">Normal T-cell activation</h2>
<ul>
<li>APC presents tumor ligand/antigen to T-cell<ul>
<li>T-cell receptor recongises antigen (first signal)</li>
<li>CD28 - B7.1/2 interaction â†’ cytokine release</li>
</ul>
</li>
<li>CTLA4 can be upregulated by tumour cells to prevent second signalling<ul>
<li>CTLA-4 will bind to T-cell</li>
<li>this cucks the B7.1/2 from binding to CD28, instead binding to the CTLA4</li>
<li>this results in no second signal â†’ T-cell anergy (i.e. no immune response)</li>
</ul>
</li>
<li>Anti-CTLA4 and Anti-PD1 can counter-cuck<ul>
<li>these antibodies will stop the cucking effect of CTLA4 or PD1</li>
<li>ipililumab (anti-CTLA4) - results in CD28/B7.1/2 binding again (second signal occurs)</li>
<li>pembrolizumab (anti-PD1) - same as above</li>
</ul>
</li>
</ul>
<p><img alt="" src="../../figures/Pasted%20image%2020231106142602.png" /></p>
<h3 id="examples_3">Examples</h3>
<ul>
<li>Increased PD-1 signalling in <a href="../Haematology/Multiple%20Myeloma.html">Multiple Myeloma</a><ul>
<li>Phase 1B trials of pembrolizumab (PD1i) in r/r MM<ul>
<li>safe but no objective response rate yet</li>
</ul>
</li>
</ul>
</li>
<li>increased PDL-1 expression in classical Hodgkin lymphoma from genetic amplification of Cr9p24.1<ul>
<li>Phase II clinical trials in R/R cHL</li>
<li>82% progression free survival</li>
<li>PBS listed for R/R cHL who have undergone or not suitable for autograft</li>
</ul>
</li>
<li>Nivolumab - anti-PD-1<ul>
<li>R/R cHL patients - nivolumab + brentuximab (CD30) before ASCT<ul>
<li>82% Objective response rate, Overall RR 61%</li>
</ul>
</li>
<li>Primary mediastinal large B-cell lymphoma<ul>
<li>amplified PD-1 axis</li>
</ul>
</li>
<li>Phase 1B study of prembrolizumab in R/R PBML<ul>
<li>Objective RR 48%</li>
</ul>
</li>
</ul>
</li>
</ul>
<hr />
<h2 id="immunomodulatory-drugs">Immunomodulatory drugs</h2>
<h2 id="examples_4">Examples</h2>
<ul>
<li>Thalidomide analogues - higher immunomodulation w/ less toxicity compared to thalidomide<ul>
<li>lenalidomide and pomalidomide<ul>
<li>increased production of IL-10 (anti-inflammatory cytokine) and production of pro-inflammatory cytokines TNF-a, IL1b, IL-6</li>
<li>induce IL-2 and IFN-y production</li>
<li>enhance T-cell and NK-cell function</li>
<li>inhibitor Treg cell activity</li>
</ul>
</li>
<li>Pomalidomide - PBS: R/R MM after failure of &gt;=2 treatment regimens including lenalidomide and bortezomib</li>
<li>Pomalidomide, bortezomib and dexamethasone - PBS: R/R MM in patients previously treated with lenalidomide</li>
<li>Daratumumab, lanilidomide, dexamethason - PBS:<ul>
<li>R/R MM after failure of at least one prior therapy</li>
<li>MM ineligible for ASCT</li>
</ul>
</li>
</ul>
</li>
<li>Thalidomide - originally used in <a href="../Haematology/Multiple%20Myeloma.html">Multiple Myeloma</a><ul>
<li>inhibition of angiogenesis and TNF-a synthesis</li>
</ul>
</li>
</ul>
<hr />
<h2 id="immunotherapeutic-vaccines">Immunotherapeutic vaccines</h2>
<h3 id="uses">Uses</h3>
<ul>
<li>AML in complete or partial remission<ul>
<li>known intracellular tumour associated antigens existing in AML (e.g.  WT1, PRTN3, MAGE)</li>
<li>vaccines not succesful in high tumor burden</li>
<li>WT1 and hTERT dendritic cell vaccines - induced cellular immune responses and associated with durable remissions</li>
</ul>
</li>
<li>not clinically used frequently</li>
</ul></div>
            </div>
        </div>

        <footer class="col-md-12">
            <hr>
                <p>Copyright &copy; 2021 Weber Liu</p>
            <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a>.</p>
        </footer>
        <script src="../../js/jquery-3.6.0.min.js"></script>
        <script src="../../js/bootstrap.min.js"></script>
        <script>
            var base_url = "../..",
                shortcuts = {"help": 191, "next": 78, "previous": 80, "search": 83};
        </script>
        <script src="../../js/base.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
        <script src="../../search/main.js"></script>

        <div class="modal" id="mkdocs_search_modal" tabindex="-1" role="dialog" aria-labelledby="searchModalLabel" aria-hidden="true">
    <div class="modal-dialog modal-lg">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="searchModalLabel">Search</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
                <p>From here you can search these documents. Enter your search terms below.</p>
                <form>
                    <div class="form-group">
                        <input type="search" class="form-control" placeholder="Search..." id="mkdocs-search-query" title="Type search term here">
                    </div>
                </form>
                <div id="mkdocs-search-results" data-no-results-text="No results found"></div>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div><div class="modal" id="mkdocs_keyboard_modal" tabindex="-1" role="dialog" aria-labelledby="keyboardModalLabel" aria-hidden="true">
    <div class="modal-dialog">
        <div class="modal-content">
            <div class="modal-header">
                <h4 class="modal-title" id="keyboardModalLabel">Keyboard Shortcuts</h4>
                <button type="button" class="close" data-dismiss="modal"><span aria-hidden="true">&times;</span><span class="sr-only">Close</span></button>
            </div>
            <div class="modal-body">
              <table class="table">
                <thead>
                  <tr>
                    <th style="width: 20%;">Keys</th>
                    <th>Action</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td class="help shortcut"><kbd>?</kbd></td>
                    <td>Open this help</td>
                  </tr>
                  <tr>
                    <td class="next shortcut"><kbd>n</kbd></td>
                    <td>Next page</td>
                  </tr>
                  <tr>
                    <td class="prev shortcut"><kbd>p</kbd></td>
                    <td>Previous page</td>
                  </tr>
                  <tr>
                    <td class="search shortcut"><kbd>s</kbd></td>
                    <td>Search</td>
                  </tr>
                </tbody>
              </table>
            </div>
            <div class="modal-footer">
            </div>
        </div>
    </div>
</div>

    </body>
</html>
